Antisense Oligonucleotide (ASO)Population PK/PDHereditary Transthyretin Amyloidosis (hATTR)

Inotersen PKPD model

Indication: Hereditary transthyretin-mediated amyloidosis polyneuropathy (hATTR-PN)

Interactive population PK/PD simulator for inotersen (Tegsedi), an antisense oligonucleotide for hereditary transthyretin amyloidosis (hATTR-PN). Two-compartment PK model with indirect response PD model based on Yu et al. 2020.

Drug Overview

Clinical Context

Drug Class
Antisense Oligonucleotide (ASO)
Therapeutic Area
Hereditary Transthyretin Amyloidosis (hATTR)
Indication
Hereditary transthyretin-mediated amyloidosis polyneuropathy (hATTR-PN)

Model Information

Model Type
Population PK/PD

This simulator was built from published pharmacometric literature using PKPDBuilder's AI-powered model extraction pipeline.

About This Simulator

This interactive pharmacokinetic simulator for Inotersen allows you to explore concentration-time profiles under different dosing scenarios. The underlying Population PK/PD model characterizes the pharmacokinetics of this antisense oligonucleotide (aso).

Use the simulator to visualize key exposure metrics including AUC (area under the curve), Cmax (peak concentration), and Ctrough (trough concentration). The pharmacodynamic component links drug exposure to therapeutic or safety endpoints.

Built with PKPDBuilder — an AI-powered platform that transforms published pharmacometric literature into interactive, deployable Shiny applications. No coding required.

Frequently Asked Questions

What is the Inotersen PK simulator?

This is a free, interactive pharmacokinetic simulator for Inotersen used in Hereditary transthyretin-mediated amyloidosis polyneuropathy (hATTR-PN). It allows researchers, pharmacologists, and students to explore concentration-time profiles, dosing regimens, and exposure metrics based on published population PK models.

What drug class does Inotersen belong to?

Inotersen is classified as a Antisense Oligonucleotide (ASO). It is used in the Hereditary Transthyretin Amyloidosis (hATTR) therapeutic area.

What type of PK model is used?

This simulator uses a Population PK/PD model. PK/PD models link drug concentrations to pharmacological effects, allowing exploration of exposure-response relationships.

Is this simulator free to use?

Yes, all PKPDBuilder simulators are completely free. They are built from published pharmacokinetic literature and are intended for research and educational purposes. No login is required to run simulations.

Can I use this for clinical dosing decisions?

No. This simulator is for research and educational purposes only. It should not be used for clinical decision-making or patient dosing. Always consult the prescribing information and clinical pharmacology guidelines for therapeutic drug use.

Related Simulators

Ready to Simulate?

Launch the Inotersen simulator to explore dosing scenarios and pharmacokinetic profiles interactively.

🚀 Launch Simulator

Comments

0/2000
Loading comments...

⚠️ Disclaimer

This simulator is for research and educational purposes only. It is not intended for clinical decision-making, patient dosing, or therapeutic drug monitoring. Pharmacokinetic parameters are derived from published literature and represent population-level estimates. Individual patient pharmacokinetics may differ significantly. Always consult approved prescribing information and qualified healthcare professionals for clinical decisions.

Powered by PKPDBuilder.com • Free pharmacokinetic simulators for the scientific community